41727-33-7 Usage
Uses
Used in Pharmaceutical Synthesis:
3-Thiophenecarbonitrile, 5-methylis used as a key intermediate in the pharmaceutical industry for the synthesis of various medicinal compounds. Its unique chemical structure allows it to be a versatile building block in the creation of new drugs, contributing to the development of novel therapeutic agents.
Used in Agrochemical Production:
In the agrochemical sector, 3-Thiophenecarbonitrile, 5-methylis employed in the production of insecticides and fungicides. Its incorporation into these products aids in the control of pests and diseases in agriculture, thereby protecting crops and enhancing yield.
Used in Chemical Research:
3-Thiophenecarbonitrile, 5-methylis also utilized in chemical research for the exploration of new reactions and the development of innovative synthetic pathways. Its reactivity and functional groups make it a valuable tool for scientists in the field of organic chemistry.
Safety Considerations:
Check Digit Verification of cas no
The CAS Registry Mumber 41727-33-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,7,2 and 7 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 41727-33:
(7*4)+(6*1)+(5*7)+(4*2)+(3*7)+(2*3)+(1*3)=107
107 % 10 = 7
So 41727-33-7 is a valid CAS Registry Number.
InChI:InChI=1/C6H5NS/c1-5-2-6(3-7)4-8-5/h2,4H,1H3
41727-33-7Relevant academic research and scientific papers
Polycyclic compound for inhibiting RNA helicase DHX33
-
Paragraph 0279-0282, (2021/04/17)
The invention relates to a polycyclic compound for inhibiting RNA helicase DHX33. In particular, the invention relates to a compound shown as a formula I or a pharmaceutically acceptable form thereof, a pharmaceutical composition containing the compound, a preparation method of the compound, and medical application of the compound to prevention and/or treatment of DHX33 related diseases.
HIV Integrase Inhibitors
-
Page/Page column 31, (2010/11/29)
The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
